Study Program to Evaluate the Prevention of Ischemia with direct Anti-Xa inhibition in Acute Coronary Syndromes 1—Thrombolysis in Myocardial Infarction 42 - SEPIA-ACS1 TIMI 42 — Presented at ESC 2009


The goal of the trial was to evaluate the efficacy and safety of the novel intravenous direct factor Xa inhibitor otamixaban in a dose-ranging manner and compared with unfractionated heparin (UFH) plus eptifibatide among patients with non-ST-elevation acute coronary syndromes (NSTE-ACS).